Navigation Links
Seahorse Bioscience and the Cancer Research UK Beatson Institute Team Up Against Cancer
Date:8/22/2013

chondrial respiration - and can do so under hypoxic conditions in real-time.

"Using the XFe96 Analyzer will enable me to decipher the different pathways of cancer cell metabolism, particularly under hypoxic conditions, which I believe is a key to new therapeutic strategies," added Dr. Gottlieb. "Once I realized that I could measure the dynamics of cancer metabolism in real-time, in a hypoxic environment, I knew we needed this technology." 

"Whenever we are able to bring together the best minds with enabling technologies we know that good things will come of it. Innovative scientific collaborations play a crucial role in finding ways to unlock the potential of new therapies, and the Beatson Institute has a strong heritage of research excellence in cancer research," said David Ferrick, Ph.D., Chief Scientific Officer at Seahorse Bioscience.  "We are excited to work with the Beatson Institute, and hope that in utilizing the power of the XF Analyzer they will gain greater understanding and potentially new discoveries regarding cancer metabolism." 

Contact
Naomi Goumillout
Marketing Communications Manager
Seahorse Bioscience
ngoumillout@seahorsebio.com

About Seahorse Bioscience
Seahorse XF instruments are the standard in cellular bioenergetic measurements. More than 700 scientists in 23 countries are utilizing the award-winning XF Analyzers to advance their research into the role of cell metabolism and its implications in cancer, aging, and metabolic, cardiovascular, and neurodegenerative diseases.  Seahorse is headquartered in Billerica, MA.  For more information, visit http://www.seahorsebio.com.

About the Beatson Institute for Cancer Research
As one of Cancer Research UK's core-funded institutes,
'/>"/>

SOURCE Seahorse Bioscience
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Seahorse Launches Reagent to Make Functional Fatty Acid Oxidation (FAO) Assays Easy
2. Seahorse Bioscience Ranks No. 1600 on the Inc. 500
3. 5000 List of Fastest-Growing Private Companies in America for 2012 with Three-Year Sales Growth of 183%
4. Seahorse Bioscience Launches First Product from the Partnership with Baystate Medical Center and UMass Amherst
5. Seahorse Bioscience Announces AACR Travel Award Recipients
6. Fitzsimons Redevelopment Authority Rolls Out First Phase of Strategic Refocus With Appointment of Four Key Leaders in The Bioscience Industry to Its Board of Directors
7. Ambit Biosciences Names Michael A. Martino President and Chief Executive Officer
8. Kansas Bioscience Authority Announces FY11 Outcomes of $207 Million
9. The Law Firm of Levi & Korsinsky, LLP Launches an Investigation Into Possible Securities Laws Violations by Pacific Biosciences of California, Inc.
10. Coronado Biosciences to Present at the Oppenheimer 22nd Annual Healthcare Conference
11. Coronado Biosciences Announces Phase 1 Results of CNDO-109 in AML to be Presented at the American Society of Hematology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)...  Vermillion, Inc. (Nasdaq:   VRML), a bio-analytical ... that the Company closed its previously announced private ... Jack W. Schuler , Birchview Fund LLC and ... before offering expenses.  The proceeds will be used ... Under the terms of the private placement, ...
(Date:12/24/2014)... (PRWEB) December 23, 2014 ... series is designed to introduce cutting edge ... users and partners of platform upgrades. This ... benefits; empowering users in their quest to ... tools. , According to SoundConnect’s Marketing Manager, ...
(Date:12/24/2014)... The report expects global cell isolation and ... also provides a carefully analyzed data about the vital ... market. , Full Copy of Report @ http://bit.ly/1yUxy0T ... for cell expansion will keep witnessing growth at an ... to be driven by rapid technological advancements, government funding ...
(Date:12/24/2014)... , Dec. 23, 2014 Sigma-Aldrich ... that the waiting period under the Hart-Scott-Rodino Antitrust ... acquisition expired on December 22, 2014, thereby completing ... requirement for the acquisition of the Company by ... antitrust clearance satisfies another condition to closing the ...
Breaking Biology Technology:Vermillion Announces Closing of Equity Financing 2Vermillion Announces Closing of Equity Financing 3SoundConnect Launches Leading Edge Business Communications Webinar Series 2SoundConnect Launches Leading Edge Business Communications Webinar Series 3The Cell Expansion Market is Expected to Reach $14.8 billion by 2019 - New Research Report by MarketsandMarkets 2The Cell Expansion Market is Expected to Reach $14.8 billion by 2019 - New Research Report by MarketsandMarkets 3Acquisition of Sigma-Aldrich by Merck KGaA, Darmstadt, Germany, Receives U.S. Antitrust Clearance 2Acquisition of Sigma-Aldrich by Merck KGaA, Darmstadt, Germany, Receives U.S. Antitrust Clearance 3
... ATLANTA, April 4, 2011 CryoLife, Inc. (NYSE: ... processing company, announced today that it has filed ... (FDA) to begin clinical trials for the purpose of obtaining ... control bleeding during surgical procedures or following traumatic injuries. ...
... ORLEANS, April 4, 2011 Orexigen ® ... additional data that showed that overweight and obese ... SR) maintained normal 24-hour circadian patterns over one ... ambulatory blood pressure monitoring (ABPM) sub-study of the ...
... (NASDAQ: OMER ), a biopharmaceutical company committed ... bleeding and disorders of the central nervous system, today ... executive officer, is scheduled to present at the 10th ... City this week.  The presentation is scheduled for Tuesday, ...
Cached Biology Technology:CryoLife Files Investigational Device Exemption (IDE) to Begin Clinical Trials for PerClot® in the U.S. 2CryoLife Files Investigational Device Exemption (IDE) to Begin Clinical Trials for PerClot® in the U.S. 3CryoLife Files Investigational Device Exemption (IDE) to Begin Clinical Trials for PerClot® in the U.S. 4Orexigen® Therapeutics Presents Additional Contrave® Data from Phase 3 COR-II Trial on 24-Hour Ambulatory Blood Pressure Monitoring 2Orexigen® Therapeutics Presents Additional Contrave® Data from Phase 3 COR-II Trial on 24-Hour Ambulatory Blood Pressure Monitoring 3Orexigen® Therapeutics Presents Additional Contrave® Data from Phase 3 COR-II Trial on 24-Hour Ambulatory Blood Pressure Monitoring 4
(Date:12/22/2014)... Dec. 22, 2014  NXT-ID, Inc. (NASDAQ: ... biometric authentication company focused on the growing mobile commerce ... security consultant, Apollo Robbins for the 2015 ... Apollo Robbins will be ... , 2015, demonstrating some of his famous theft techniques ...
(Date:12/19/2014)... 18, 2014  23andMe, Inc., the leading personal genetics ... pinpoints fine-scale differences in genetic ancestry of individuals from ... Since immigrants first arrived more than four hundred ... has served as a meeting place for peoples from ... the ongoing mixing of peoples with African, European, and ...
(Date:12/17/2014)... Dec. 16, 2014 Valencell, a leader in ... biometric technology to industry leaders such as Intel, Jabra, ... validated, biometric wearable products. These products will be showcased ... Las Vegas . "Our ... flexible and robust – with the clinical data to ...
Breaking Biology News(10 mins):NXT-ID Hires Master Pickpocket and Security Consultant Apollo Robbins for Wocket Smart Wallet CES 2015 Debut 2NXT-ID Hires Master Pickpocket and Security Consultant Apollo Robbins for Wocket Smart Wallet CES 2015 Debut 3NXT-ID Hires Master Pickpocket and Security Consultant Apollo Robbins for Wocket Smart Wallet CES 2015 Debut 423andMe Study Sketches Genetic Portrait of the United States 223andMe Study Sketches Genetic Portrait of the United States 323andMe Study Sketches Genetic Portrait of the United States 4Valencell PerformTek Biometrics Power the Most Accurate Wearables at CES 2015 2
... and FRAMINGHAM, Mass. , Feb. ... and TruTouch Technologies, Inc. today announced that they have signed ... biometric test in the US.  The workplace sobriety assurance solution ... quickly and accurately measures alcohol consumption. This is simply done ...
... in the H5N1 avian influenza virus that affects the pH ... its capacity to infect ducks and enhances its capacity to ... today in the Journal of Virology . ... of a virus in one host species, tissue, or cell ...
... 2013 -- A range of new and promising targeted ... be presented during the 11th International Congress on Targeted ... event, which is organised by NDDO Education Foundation, is ... Cancer Institute. Over 500 oncologists and scientists ...
Cached Biology News:Psychemedics & TruTouch Announce US Sales/Marketing Distribution Agreement For TruTouch Technologies' Rapid Optical Alcohol Detection & Biometric Test 2Psychemedics & TruTouch Announce US Sales/Marketing Distribution Agreement For TruTouch Technologies' Rapid Optical Alcohol Detection & Biometric Test 3Psychemedics & TruTouch Announce US Sales/Marketing Distribution Agreement For TruTouch Technologies' Rapid Optical Alcohol Detection & Biometric Test 4Mutation altering stability of surface molecule in acid enables H5N1 infection of mammals 2Mutation altering stability of surface molecule in acid enables H5N1 infection of mammals 311th International Congress on Targeted Anticancer Therapies 2
... D kit is an enzymeimmunoassay intended ... D (25-OH D) and other hydroxylated ... Our patented DIRECT assay technology eliminates ... centrifugation and therefore facilitates automation on ...
... A multi-purpose, high gel-strength agarose suitable ... techniques, from conventional constant field to Pulsed ... high gel strength and exclusion limits, Multi ... with reduced running times. This in turn ...
Mouse monoclonal [1.F.1] to Yersinia pestis F1 antigen ( Abpromise for all tested applications). Antigen: Purified F1 antigen of Y. pestis vaccine strain EB....
Rabbit polyclonal to L Kynurenine ( Abpromise for all tested applications). Antigen: Synthetic peptide L Kynurenine conjugated to a protein carrier. Entrez Gene ID: 8942 Swiss Protein ID...
Biology Products: